Novel nano-membrane technology to enable development of therapeutic antibodies targeting membrane proteins
| Reference number | |
| Coordinator | Salipro Biotech AB |
| Funding from Vinnova | SEK 630 000 |
| Project duration | November 2018 - December 2019 |
| Status | Completed |
Purpose and goal
More than 60% of all current drugs target membrane proteins, with a global market size exceeding $ 200 billion per year. However, membrane proteins are inherently unstable. This instability represents a major challenge for the pharmaceutical industry. Salipro Biotech has developed a proprietary nano-membrane technology (Salipro®) stabilizing those important membrane proteins, making them accessible for drug development. The aim of the project is to deliver proof of concept data, proving the industry value of the Salipro® technology in the development of therapeutic antibodies
Expected results and effects
Generated data showed that the Salipro® technology could successfully be used to produce membrane protein specific monoclonal antibodies. This proof of concept data is very promising and supports further investments into the project idea. The data will be used for publication and will lead to larger innovation projects and initiate industry collaborations.
Planned approach and implementation
The project is a collaboration between Salipro Biotech and Helena Persson Lotsholm, Head of the Human Antibody Therapeutics facility at the Drug Discovery & Development (DDD) platform at the Science for Life Laboratory (SciLifeLab). Salipro Biotech reconstituted membrane proteins into Salipro nanoparticles , while antibody generation by phage display was conducted at SciLifeLab.